![George Ludwig](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
George Ludwig
Corporate Officer/Principal chez
ConPharm Anstalt
Profil
Mr. Georg Ludwig is Managing Limited Partner at HighTech Private Equity GmbH
George Ludwig has been a Managing Director of ConPharm Anstalt since 2005 and a Director of Lorus Therapeutics, Inc. since September 2006.
Previously, he was a Managing Director of HighTech Private Equity from 2000 to 2004.
Postes actifs de George Ludwig
| Sociétés | Poste | Début |
|---|---|---|
ConPharm Anstalt | Corporate Officer/Principal | 01/01/2005 |
Anciens postes connus de George Ludwig
| Sociétés | Poste | Fin |
|---|---|---|
High Tech Private Equity GmbH
 High Tech Private Equity GmbH Investment ManagersFinance HTPE is a hands-on manager which takes majority and minority stakes in technology oriented companies in the following sectors: microelectronics, nanotechnology, sensor technology, microsystem technology, optics, optoelectronics, innovative engineering technology and robotics, life sciences, biotech and pharmaceuticals, medical technology and other high-tech sectors (excluding internet and software). They invest in all countries, and in particular in Austria, Canada, Germany, Switzerland, the US and Western Europe. For companies in the expansion phase, the firm typically seeks to invest EUR 2-5 million in companies with developed technology, marketable products, initial revenues with high development potential and management with high technological competence, a strong marketing orientation and a clear strategy. For established mittelstand companies, HTPE seeks to invest EUR 3-10 million in businesses with a turnover of EUR 20-25 million, an established, well structured market position, above-average growth potential for the sector and a management team with a high level of market expertise, a strategic way of thinking and the vision to become a market leader. The firm generally invests EUR 5-10 million in pharmaceutical and biotech companies developing new chemical/biological entities or new products and will only invest in new drug delivery technologies in combination with concrete product development. Their investment criteria include the therapeutic indication, its associated market potential and the availability of a valid patent or patent portfolio. HTPE's investment committee makes the firm's investment decisions. | Corporate Officer/Principal | 01/01/2004 |
| APTOSE BIOSCIENCES INC. | Directeur/Membre du Conseil | 03/03/2010 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
13
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Aptose Biosciences, Inc.
 Aptose Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Discovers, research and develops anticancer therapies with high safety profiles | Health Technology |
High Tech Private Equity GmbH
High Tech Private Equity GmbH Investment ManagersFinance HTPE is a hands-on manager which takes majority and minority stakes in technology oriented companies in the following sectors: microelectronics, nanotechnology, sensor technology, microsystem technology, optics, optoelectronics, innovative engineering technology and robotics, life sciences, biotech and pharmaceuticals, medical technology and other high-tech sectors (excluding internet and software). They invest in all countries, and in particular in Austria, Canada, Germany, Switzerland, the US and Western Europe. For companies in the expansion phase, the firm typically seeks to invest EUR 2-5 million in companies with developed technology, marketable products, initial revenues with high development potential and management with high technological competence, a strong marketing orientation and a clear strategy. For established mittelstand companies, HTPE seeks to invest EUR 3-10 million in businesses with a turnover of EUR 20-25 million, an established, well structured market position, above-average growth potential for the sector and a management team with a high level of market expertise, a strategic way of thinking and the vision to become a market leader. The firm generally invests EUR 5-10 million in pharmaceutical and biotech companies developing new chemical/biological entities or new products and will only invest in new drug delivery technologies in combination with concrete product development. Their investment criteria include the therapeutic indication, its associated market potential and the availability of a valid patent or patent portfolio. HTPE's investment committee makes the firm's investment decisions. | Finance |
ConPharm Anstalt |
